The assumption of chemotherapy-related formation of thrombosis is generally in accord with both, findings on the laboratory level e.g. increased levels of von Willebrand factor and other thrombosis-associated factors in patients receiving cisplatinum [14,15] as well as with cisplatin-induced hypomagnesemia and with clinical observations of arterial thromboses and even myocardial infarctions in TGCT patients undergoing chemotherapy [4]. The gene discussed is VWF; the disease is myocardial infarction.